万春医药 BYSI 深 沪
已收盘 09-12 16:00:00 美东时间
1.82
-0.050
-2.67%
华盛通- 最 高1.8792
- 今 开1.8792
- 成交量 9682股
- 最 低 1.82
- 昨 收 1.87
- 总市值 7340.48万
- 52周最高 3.44
- 市盈率 静 --
- 换手率 0.02%
- 52周最低 0.98
- 委 比 61.02%
- 总股本 4033.23万
- 历史最高 48.49
- 量 比 0.40
- 振 幅 3.17%
- 历史最低 0.542
- 每 手 1
- 风险率 0.76%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Beyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in Japan
Beyond Air公司扩展其LungFit PH全球分销网络，新增日本、韩国等六国，总计覆盖34国，人口27亿。日本由70年经验的AMCO负责。CEO Steve Lisi表示，此举加强了国际市场影响力，正在等待监管审批并提交招标。LungFit PH利用环境空气生成一氧化氮，无需高压气瓶，提升医院效率并减少环境影响，助力 Breath
08-20 12:00
BeyondSpring GAAP EPS of -$0.10
BeyondSpring press release (NASDAQ:BYSI): Q2 GAAP EPS of -$0.10. Cash and cash equivalents: $9.5 million as of June 30, 2025, compared to $2.9 million as of December 2024 More on BeyondSpring Financ...
08-13 22:10
BeyondSpring Q2 EPS $(0.04) Up From $(0.10) YoY
BeyondSpring (NASDAQ:BYSI) reported quarterly losses of $(0.04) per share. This is a 60 percent increase over losses of $(0.10) per share from the same period last year.
08-13 20:04
BeyondSpring Drug Triggers Immune Response in Patients Who Failed Prior Cancer Immunotherapy
BeyondSpring Inc. (NASDAQ:BYSI) today announced publication of a human clinical study in Med (Cell Press) demonstrating that Plinabulin, when combined with radiation and a checkpoint inhibitor, induces
07-07 19:04
BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure
BeyondSpring Inc.的Plinabulin在与放疗和PD-1抑制剂联合治疗中，在8种肿瘤类型中取得23%客观缓解率和54%疾病控制率。研究揭示GEF-H1免疫基因表达可能是预测性生物标志物，并证实Plinabulin通过GEF-H1信号促进树突状细胞成熟，增强抗肿瘤免疫反应。该研究发表在《Med》杂志上。
07-07 11:00
小坑，2只打新！
关键指标【仅供参考】 1、沪深300股债利差择时模型：6.17%，维持100%偏股基金。（持有资金或新增资金均配置节节高混合/雄霸赛道偏股等组合）。 2、万得全...
06-11 08:15
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
BeyondSpring Inc. announced interim phase 2 data from the 303 Study at the 2025 ASCO Annual Meeting. The study evaluated Plinabulin, pembrolizumab, and docetaxel in 47 metastatic NSCLC patients who progressed on PD-1/L1 inhibitors. Key results include a median PFS of 6.8 months, a Disease Control Rate of 77.3%, and a 15-month OS rate of 78%, with the combination well-tolerated. The data suggest Plinabulin's potential to reverse resistance to chec...
06-03 11:00
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting
BeyondSpring Inc. will present a poster at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, highlighting the 303 Study on the combination of pembrolizumab, plinabulin, and docetaxel for patients with metastatic NSCLC who progressed on first-line immune checkpoint inhibitors. The presentation, titled "Phase 2 Study of Pembrolizumab (Pembro) plus Plinabulin (Plin) and Docetaxel (Doc)...", will discuss initial efficac...
05-28 11:00
BeyondSpring GAAP EPS of -$0.08
BeyondSpring press release (NASDAQ:BYSI): Q1 GAAP EPS of -$0.08. Cash and cash equivalents of $2.92 million. More on BeyondSpring Financial information for BeyondSpring
05-13 05:25
